Published in J Hematol Oncol on August 15, 2011
Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One (2012) 1.42
A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type. J Hematol Oncol (2013) 1.20
Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party. Blood Res (2013) 0.96
Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma. BMC Cancer (2013) 0.92
The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer. BMC Cancer (2013) 0.84
The relationship of T helper-2 pathway components interleukin-4, interleukin-10, immunoglobulin e, and eosinophils with prognostic markers in non-hodgkin lymphoma: a case-control study. Turk J Haematol (2014) 0.75
L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma. Exp Ther Med (2016) 0.75
Negative prognostic impact of low absolute CD4(+) T cell counts in peripheral blood in mantle cell lymphoma. Cancer Sci (2016) 0.75
Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma: A case report. Medicine (Baltimore) (2016) 0.75
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med (1993) 17.71
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med (1998) 8.24
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol (2008) 6.90
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood (2003) 2.56
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res (2009) 2.51
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res (2010) 2.50
Cellular and molecular pathways linking inflammation and cancer. Immunobiology (2009) 1.78
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood (2011) 1.57
Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma (2010) 1.54
T-cell non-Hodgkin lymphoma. Blood (2005) 1.53
Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer (2005) 1.53
CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer (2004) 1.35
Peripheral T-cell lymphomas. Blood Rev (2007) 1.17
Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma (2008) 1.16
Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol (2008) 1.16
Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia (2005) 1.14
Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol (2009) 1.14
Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol (2007) 1.14
Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia (2007) 1.14
Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol (2008) 1.13
Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol (2010) 1.07
Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res (2004) 1.04
Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol (2010) 0.99
Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol (2007) 0.98
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia (2010) 0.96
Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma. Br J Haematol (2008) 0.93
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood (2007) 0.87
A TRPV family ion channel required for hearing in Drosophila. Nature (2003) 3.53
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol (2011) 3.10
Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol (2005) 2.90
Two interdependent TRPV channel subunits, inactive and Nanchung, mediate hearing in Drosophila. J Neurosci (2004) 2.66
Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol (2003) 2.64
SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood (2012) 2.29
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol (2010) 2.27
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys (2005) 2.19
Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol (2009) 2.13
Hybrid epicardial and endocardial ablation of persistent or permanent atrial fibrillation: a new approach for difficult cases. J Cardiovasc Electrophysiol (2007) 1.97
Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma (2009) 1.83
Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol (2002) 1.82
Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circ J (2012) 1.79
Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol (2012) 1.77
Usefulness of whole-blood interferon-gamma assay and interferon-gamma enzyme-linked immunospot assay in the diagnosis of active pulmonary tuberculosis. Chest (2007) 1.75
The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood (2007) 1.74
Primary pulmonary non-Hodgkin's lymphoma. Jpn J Clin Oncol (2004) 1.70
Clinical characteristics of Korean pediatric patients critically ill with influenza A (H1N1) virus. Pediatr Pulmonol (2010) 1.70
Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol (2007) 1.65
Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. Leuk Res (2006) 1.60
Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion (2009) 1.57
TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. Genes Chromosomes Cancer (2008) 1.56
Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res (2007) 1.56
Time course for inhibition of lipopolysaccharide-induced lung injury by genistein: relationship to alteration in nuclear factor-kappaB activity and inflammatory agents. Crit Care Med (2003) 1.52
Is empirical four pulmonary vein isolation necessary for focally triggered paroxysmal atrial fibrillation? Comparison of selective pulmonary vein isolation versus empirical four pulmonary vein isolation. J Cardiovasc Electrophysiol (2008) 1.52
Clinical features and treatment outcomes of intravascular large B-cell lymphoma: a single-center experience in Korea. Acta Haematol (2013) 1.50
Crystal structure of the Mre11-Rad50-ATPγS complex: understanding the interplay between Mre11 and Rad50. Genes Dev (2011) 1.45
Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP. Acta Haematol (2013) 1.45
Outcome and predictors of mortality in patients requiring invasive mechanical ventilation due to acute respiratory failure while undergoing ambulatory chemotherapy for solid cancers. Support Care Cancer (2013) 1.44
Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. Leuk Lymphoma (2011) 1.43
Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome. Acta Haematol (2015) 1.42
Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab. Ophthalmology (2008) 1.40
Clinical influence of early follow-up glycosylated hemoglobin levels on cardiovascular outcomes in diabetic patients with ST-segment elevation myocardial infarction after coronary reperfusion. Coron Artery Dis (2015) 1.39
Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification. Ann Hematol (2014) 1.39
Central nervous system multiple myeloma: a different cytogenetic profile? Br J Haematol (2013) 1.38
Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). J Hematol Oncol (2012) 1.37
Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol (2002) 1.34
Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res (2004) 1.30
Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer (2005) 1.28
Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int (2013) 1.27
A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol (2012) 1.24
Single transcription factor reprogramming of hair follicle dermal papilla cells to induced pluripotent stem cells. Stem Cells (2011) 1.22
Do glycemic markers predict occurrence of complications after total knee arthroplasty in patients with diabetes? Clin Orthop Relat Res (2014) 1.21
DeSUMOylating isopeptidase: a second class of SUMO protease. EMBO Rep (2012) 1.18
Preanesthetic dexmedetomidine 1 µg/kg single infusion is a simple, easy, and economic adjuvant for general anesthesia. Korean J Anesthesiol (2013) 1.17
Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol (2013) 1.17
Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica (2010) 1.16
A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep (2006) 1.15
Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br J Haematol (2003) 1.15
Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol (2013) 1.14
Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer (2010) 1.14
Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. Am J Hematol (2014) 1.13
Early experiences of robotic-assisted laparoscopic liver resection. Yonsei Med J (2008) 1.13
Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant (2008) 1.13
Relationship Between the Number of Residency Applications and the Yearly Match Rate: Time to Start Thinking About an Application Limit? J Grad Med Educ (2015) 1.13
Isolated extramedullary relapse of acute myelogenous leukemia as a uterine granulocytic sarcoma in an allogeneic hematopoietic stem cell transplantation recipient. Yonsei Med J (2004) 1.13
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol (2010) 1.11
An outbreak of novel influenza A (H1N1) in the English Language Institute. J Prev Med Public Health (2010) 1.10
Primary angiosarcoma of the pulmonary trunk mimicking pulmonary thromboembolism. Echocardiography (2010) 1.09
Fatal cases of 2009 pandemic influenza A (H1N1) in Korea. J Korean Med Sci (2010) 1.09
Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol (2007) 1.08
Activation of CXCR2 by extracellular matrix degradation product acetylated Pro-Gly-Pro has therapeutic effects against sepsis. Am J Respir Crit Care Med (2011) 1.08
Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer (2012) 1.08
Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci (2012) 1.07
Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models. Blood (2012) 1.06
Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol (2009) 1.06
Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood (2010) 1.06
Anti-inflammatory effects of Asparagus cochinchinensis extract in acute and chronic cutaneous inflammation. J Ethnopharmacol (2008) 1.05